GlassScriptPhysician profile
Neha D Robinson
NPI 1669407052
$16,518.37
in general payments reported to CMS, 2019-2025
37 companies · $2,134 in 2025
The $2,134 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,189 · 2020: $1,973 · 2021: $1,887 · 2022: $2,598 · 2023: $2,228 · 2024: $2,509 · 2025: $2,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,674 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,674.23 |
| Education | $196.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,407.10 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Sun Pharmaceutical Industries INC. | $1,480.02 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $1,329.56 | 2021-2025 | Tremfya |
| Prugen, INC. Pharmaceuticals | $1,068.66 | 2019-2021 | |
| Allergan, INC. | $972.15 | 2019-2022 | |
| Almirall LLC | $936.92 | 2019-2024 | Klisyri |
| Genzyme Corporation | $849.55 | 2019-2025 | |
| Lilly USA, LLC | $819.62 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $652.83 | 2019-2025 | |
| Galderma Laboratories, L.P. | $616.84 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Incyte Corporation | $577.72 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $568.95 | 2019-2025 | Dupixent |
| Ucb, INC. | $562.26 | 2019-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $470.23 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Leo Pharma INC. | $415.36 | 2019-2025 | Adbry |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $409.73 | 2019-2024 | |
| Amgen INC. | $392.34 | 2019-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $298.10 | 2019-2025 | |
| Dermavant Sciences, INC. | $274.91 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $199.52 | 2023-2025 | Zoryve |
| Dermira, INC. | $181.93 | 2019-2020 | |
| Merz North America, INC. | $166.58 | 2019 | |
| Epi Health, LLC | $161.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.93 | 2023-2025 | Spevigo, Cyltezo |
| Fresenius Kabi USA, LLC | $126.26 | 2023-2025 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $80.27 | 2023-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $78.04 | 2020-2021 | |
| Organon LLC | $55.86 | 2025 | Vtama |
| Celgene Corporation | $47.70 | 2019 | |
| Mylan Pharmaceuticals INC. | $38.44 | 2019 | |
| Mission Pharmacal Company | $34.69 | 2019 | |
| Verrica Pharmaceuticals INC. | $26.81 | 2025 | Ycanth |
| Organogenesis INC. | $18.76 | 2023 | Puraply |
| Revance Therapeutics, INC. | $18.04 | 2024 | Daxxify |
| Biofrontera INC. | $16.79 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Dusa Pharmaceuticals, INC. | $14.78 | 2019 | |
| Encore Dermatology INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.